PCH HemOnc Tumor Board 2025 PCH HemOnc Tumor Board 2025 - 5/8/2025

May 8, 2025 – 12:15 PM

Online

Overall Activity Objectives:

1 Select the most appropriate diagnostic strategy for a patient with a suspected pediatric oncologic condition

2 Employ up-to-date treatment options, including targeted therapies

3 Coordinate histologic with molecular diagnoses

4 Closely follow patients radiographically and by other disease work-up

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Arizona College of Medicine - Tucson and Phoenix Children's The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Laura L Retson, DO	Faculty	Nothing to disclose - 01/06/2025
Dana Salzberg, MD		Speakers Bureau-Jazz Pharmaceuticals, Inc 01/06/2025
Mallery Olsen, MD	Planning Committee Member	Nothing to disclose - 01/09/2025
Alexandra Walsh, Other	Faculty	Nothing to disclose - 05/07/2025
James Williams, MD	Faculty	Nothing to disclose - 01/07/2025
Natasha S Bala, MD	Faculty	Nothing to disclose - 05/07/2025

